CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines™ (formerly FogPharma), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer, today announced a corporate name change. The company’s new name, Parabilis (pronounced puh-RAH-buh-liss), draws on Greek and Latin etymologies to mean both ‘beyond what’s possible’ and ‘obtainable,’ reflecting the company’s drive to expand what is therapeutically possible for the treatment of serious diseases, and its commitment to ensuring its medicines reach and benefit patients globally..

马萨诸塞州剑桥市。-（商业新闻短讯）--Parabilis Medicines™（前身为FogPharma）是一家临床阶段的生物制药公司，致力于为癌症患者创造非凡的药物，今天宣布更改公司名称。该公司的新名称Parabilis（发音为puh RAH buh liss）借鉴了希腊语和拉丁语词源，意味着“超越可能”和“可获得”，反映了该公司努力扩大治疗严重疾病的治疗可能性，并致力于确保其药物惠及全球患者。。

Parabilis also unveiled its expanded Helicon™ platform, which seamlessly integrates highly innovative AI and experimental technologies to discover, optimize, and deliver Helicon peptide therapeutics for not-yet-drugged targets, in addition to cutting-edge data science techniques the company is employing to optimize trial design and guide future clinical strategies..

Parabilis还推出了其扩展的Helicon™平台，该平台无缝集成了高度创新的人工智能和实验技术，以发现、优化和提供针对尚未用药靶标的Helicon肽疗法，此外，该公司还采用了前沿数据科学技术来优化试验设计并指导未来的临床策略。。

“The name Parabilis captures the tremendous aspirations of a group of passionate innovators who are grounded in pragmatism. We are combining breakthrough science, industry-leading artificial intelligence (AI) capabilities, and a relentless drive to create real medicines that change what is possible in treating disease,” said Mathai Mammen, M.D., Ph.D., Chairman and CEO of Parabilis Medicines.

Parabilis medicines董事长兼首席执行官Mathai Mammen博士说：“Parabilis这个名字抓住了一群以实用主义为基础的充满激情的创新者的巨大愿望。我们将突破性的科学、业界领先的人工智能（AI）能力以及创造真正药物的不懈努力相结合，以改变治疗疾病的可能性。”。

“That clarity of ambition is reflected in the way we approach our work, integrating data science and new product planning throughout the drug discovery and development lifecycle to ensure we’re single-mindedly pursuing only those medicines that anticipate and address profound unmet needs. Our new company name embodies this spirit: break boundaries, crush dogma, operate with the highest ambitions, and focus relentlessly on the patient at all times.”.

“雄心壮志的清晰体现在我们对待工作的方式上，在整个药物发现和开发生命周期中整合数据科学和新产品规划，以确保我们只专注于那些能够预测和解决严重未满足需求的药物。我们的新公司名称体现了这种精神：打破界限，打破教条，以最高的雄心壮志运营，并始终专注于患者。”。

Parabilis’s investigational lead candidate, FOG-001, is the only clinical-stage inhibitor of the interaction of β-catenin with TCF, a known driver of colorectal cancer (CRC) with a significant role in multiple additional cancers. This target has been a towering challenge in the pharmaceutical industry, known for decades to be a key node, yet intractable.

Parabilis的研究主要候选药物FOG-001是β-连环蛋白与TCF相互作用的唯一临床阶段抑制剂，TCF是结直肠癌（CRC）的已知驱动因素，在多种其他癌症中起着重要作用。这一目标在制药行业一直是一个严峻的挑战，几十年来，制药行业一直被认为是一个关键节点，但仍然难以实现。

Now 16 months into its development, FOG-001 continues to enroll mostly CRC patients in its Phase 1 precision guided program. The company is also advancing its discovery portfolio with applications in protein degraders and radioligand therapies for the treatment of cancer, with four late discovery programs and integration of AI and advanced data science into every aspect of the discovery and development process..

FOG-001开发16个月后，继续在其第一阶段精确引导计划中招募大部分CRC患者。该公司还在推进其发现组合，将其应用于蛋白质降解剂和放射性配体疗法治疗癌症，并有四个晚期发现计划，并将人工智能和先进数据科学整合到发现和开发过程的各个方面。。

In early 2024, the company raised a $145 million Series E financing to support the ongoing clinical development of FOG-001 and accelerate its broader Helicon peptide portfolio and platform.

2024年初，该公司筹集了1.45亿美元的E系列融资，以支持FOG-001的持续临床开发，并加速其更广泛的螺旋肽组合和平台。

About Parabilis Medicines (Formerly FogPharma)

Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through its pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets.

Parabilis Medicines™是一家临床阶段的生物制药公司，致力于为癌症患者创造非凡的药物。通过其开创性的Helicon™发现平台，Parabilis正在设计精确调整，稳定的螺旋肽疗法，这些疗法有可能解锁大量传统上不可药用的靶标。

FOG-001, the company’s first-in-class TCF-blocking β-catenin inhibitor and lead clinical program, is being evaluated in a Phase 1/2 study for patients with colorectal cancer and other solid tumors and is proof of the applicability of the platform to address undruggable intracellular protein-protein targets.

FOG-001是该公司第一个一流的TCF阻断β-连环蛋白抑制剂和主要临床项目，正在针对结直肠癌和其他实体瘤患者的1/2期研究中进行评估，证明该平台适用于解决不可治疗的细胞内蛋白质-蛋白质靶标。

The company is additionally advancing a pipeline of other first-in-class programs that target proteins known to be relevant to numerous cancers, but considered intractable with traditional drug modalities. The versatility of the Helicon approach allows for the discovery of multiple targeting mechanisms, including functional protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics.

另外，该公司正在推进一系列其他一流项目，这些项目针对已知与多种癌症相关但被认为与传统药物模式难以治疗的蛋白质。Helicon方法的多功能性允许发现多种靶向机制，包括功能性蛋白质-蛋白质相互作用抑制剂，双功能降解剂和放射性配体治疗剂。

Parabilis is headquartered in Cambridge, Mass., and is well-capitalized, with more than $500 million raised to date from leading life sciences investors. For more information, please visit: www.parabilismed.com.

Parabilis总部位于马萨诸塞州剑桥市，资本充足，迄今已从领先的生命科学投资者那里筹集了5亿多美元。有关更多信息，请访问：www.parabilismed.com。